We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Feb 2021 - 28 Feb 2021
Virtual Venue

Microneedle Patch Delivers Long-Acting Contraceptive

By HospiMedica International staff writers
Posted on 31 Jan 2019
Print article
Image: Professor Mark Prausnitz holds an experimental microneedle contraceptive skin patch (Photo courtesy of Christopher Moore/Georgia Tech).
Image: Professor Mark Prausnitz holds an experimental microneedle contraceptive skin patch (Photo courtesy of Christopher Moore/Georgia Tech).
A new study shows how a long-acting contraceptive designed for self-administration could provide a new family planning option, particularly in developing nations.

Developed by researchers at the Georgia Institute of Technology (Georgia Tech; Atlanta, GA, USA) and the University of Michigan (U-M; Ann Arbor, USA), the novel patch is made of 100 microneedles molded from a blend of polylactic-co-glycolic acid (PLGA) and polylactic acid (PLA), two biodegradable polymers commonly used in sutures. Bubble structures situated in the patch backing allow the microneedles to penetrate skin under compression, and snap off under shear force within five seconds of patch administration.

The microneedles provide continuous, sustained release of the contraceptive hormone levonorgestrel. In a study in rats, the microneedle patch was well tolerated, leaving little visible evidence of use, and maintained plasma concentrations of the hormone above the human therapeutic level for one month. The researchers suggest that further development of the rapidly separable microneedle patch for self-administered, long-acting contraception could enable women to better control their fertility. The study was published on January 14, 2019, in Nature Biomedical Engineering.

“Our goal is for women to be able to self-administer long-acting contraceptives with the microneedle patch that would be applied to the skin for five seconds just once a month,” said corresponding author Professor Mark Prausnitz, PhD, of Georgia Tech. “We do not yet know how the contraceptive microneedle patches would work in humans. Because we are using a well-established contraceptive hormone, we are optimistic that the patch will be an effective contraceptive.”

Long-acting contraceptives are available in formats such as patches that must be worn continuously, intrauterine devices (IUDs) that must be placed by trained healthcare professionals, and drugs injected with hypodermic needles. If the microneedle contraceptive patch is ultimately approved for use, it could become the first self-administered, long-acting contraceptive that does not involve a conventional needle injection.

Related Links:
Georgia Institute of Technology
University of Michigan

Print article



view channel

Hillrom Acquires Bardy Diagnostics to Expand into Ambulatory Cardiac Monitoring Segment

Hillrom (Chicago, IL, USA) has reached a definitive agreement to acquire Bardy Diagnostics, Inc. (BardyDx; Seattle, WA, USA) for a cash consideration of USD 375 million. The acquisition of BardyDx,... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.